A
Arena Pharmaceuticals Inc
F:RN3N
Arena Pharmaceuticals Inc
F:RN3N
Price:
90.5
EUR
0.56%
Market Closed
Market Cap:
€5.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Arena Pharmaceuticals Inc
F:RN3N
|
US |
|
Nova Eye Medical Ltd
ASX:EYE
|
AU |
|
Starpharma Holdings Ltd
ASX:SPL
|
AU |
|
B
|
B'IN Live Co Ltd
TWSE:6625
|
TW |
|
Sharp Corp
TSE:6753
|
JP |
|
Eco Atlantic Oil & Gas Ltd
XTSX:EOG
|
CA |
|
Gyldendal ASA
OSE:GYL
|
NO |
|
CareDx Inc
NASDAQ:CDNA
|
US |
|
B
|
Bear Creek Mining Corp
XTSX:BCM
|
CA |
|
NK Russneft' PAO
MOEX:RNFT
|
RU |
|
G
|
Grande Asset Hotels and Property PCL
SET:GRAND
|
TH |
Balance Sheet
Balance Sheet Decomposition
Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Balance Sheet
Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Currency: USD
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
156
|
222
|
163
|
156
|
91
|
159
|
161
|
243
|
220
|
225
|
|
| Cash Equivalents |
156
|
222
|
163
|
156
|
91
|
159
|
161
|
243
|
220
|
225
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
88
|
285
|
496
|
885
|
326
|
|
| Total Receivables |
6
|
11
|
4
|
5
|
20
|
14
|
5
|
2
|
0
|
0
|
|
| Accounts Receivables |
6
|
11
|
4
|
5
|
20
|
2
|
5
|
2
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
12
|
0
|
0
|
0
|
0
|
|
| Inventory |
6
|
13
|
11
|
10
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
4
|
4
|
4
|
4
|
2
|
20
|
10
|
19
|
35
|
19
|
|
| Total Current Assets |
171
|
249
|
182
|
175
|
120
|
281
|
461
|
760
|
1 139
|
569
|
|
| PP&E Net |
75
|
77
|
83
|
72
|
44
|
30
|
23
|
37
|
33
|
28
|
|
| PP&E Gross |
75
|
77
|
83
|
72
|
44
|
30
|
23
|
37
|
33
|
28
|
|
| Accumulated Depreciation |
84
|
88
|
92
|
101
|
65
|
58
|
46
|
49
|
53
|
56
|
|
| Intangible Assets |
11
|
10
|
9
|
8
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
24
|
82
|
371
|
0
|
161
|
|
| Other Long-Term Assets |
4
|
3
|
3
|
2
|
3
|
4
|
121
|
6
|
19
|
26
|
|
| Total Assets |
261
N/A
|
340
+30%
|
276
-19%
|
257
-7%
|
169
-34%
|
339
+101%
|
687
+102%
|
1 174
+71%
|
1 191
+1%
|
785
-34%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4
|
4
|
3
|
2
|
6
|
2
|
6
|
6
|
12
|
13
|
|
| Accrued Liabilities |
6
|
8
|
14
|
11
|
10
|
38
|
20
|
35
|
42
|
48
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
2
|
3
|
3
|
4
|
4
|
3
|
4
|
4
|
5
|
|
| Other Current Liabilities |
18
|
57
|
48
|
34
|
44
|
29
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
30
|
71
|
67
|
50
|
64
|
72
|
30
|
45
|
58
|
66
|
|
| Long-Term Debt |
73
|
71
|
68
|
65
|
62
|
58
|
49
|
46
|
41
|
36
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
60
|
107
|
93
|
88
|
3
|
2
|
1
|
12
|
11
|
9
|
|
| Total Liabilities |
163
N/A
|
248
+53%
|
229
-8%
|
203
-11%
|
129
-36%
|
132
+2%
|
81
-39%
|
103
+27%
|
110
+7%
|
111
+1%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1 188
|
1 208
|
1 268
|
1 376
|
1 399
|
1 490
|
1 501
|
1 103
|
1 508
|
2 124
|
|
| Additional Paid In Capital |
1 281
|
1 294
|
1 313
|
1 431
|
1 442
|
1 699
|
2 107
|
2 173
|
2 588
|
2 798
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
6
|
6
|
3
|
1
|
3
|
1
|
0
|
1
|
1
|
0
|
|
| Total Equity |
99
N/A
|
92
-7%
|
47
-49%
|
54
+13%
|
40
-25%
|
207
+419%
|
606
+193%
|
1 072
+77%
|
1 081
+1%
|
673
-38%
|
|
| Total Liabilities & Equity |
261
N/A
|
340
+30%
|
276
-19%
|
257
-7%
|
169
-34%
|
339
+101%
|
687
+102%
|
1 174
+71%
|
1 191
+1%
|
785
-34%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
22
|
22
|
22
|
24
|
24
|
39
|
49
|
50
|
59
|
62
|
|
Switch to:
Switch to:
See Also
Discover More
